Neuvivo
Palo Alto, United States· Est. 2015
First immunotherapy for ALS. Targeting the immune system at the earliest manifestation of neurodegenerative diseases.
Private Company
Total funding raised: $65M
About
First immunotherapy for ALS. Targeting the immune system at the earliest manifestation of neurodegenerative diseases.
Small Molecules
Funding History
2Total raised:$65M
Series B$40MAug 15, 2021
Series A$25MApr 15, 2019